The US Food and Drug Administration (FDA) has granted priority review to United Kingdom-based AstraZeneca's cancer drug Imfinzi (durvalumab) intended for the treatment of extensive-stage small cell lung cancer (SCLC) in earlier untreated patients, it was reported on Friday.
The company has submitted the drug's supplemental Biologics License Application for its approval in extensive SCLC in treatment-naive patients based on the results from the phase three CASPIAN trial. AstraZeneca has said that results from the phase 3 trial showed an estimated 33.9% of patients survived at 18 months after receiving the investigational treatment compared to 24.7% of patients who were on SoC treatment.
The product's Prescription Drug User Fee Act (PUDFA) date for the SCLC indication has been set for the first quarter of 2020 by the US FDA. The oncology immunotherapy was earlier granted orphan drug designation for the same indication by the US FDA in July 2019.
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Implantica produces 10,000 RefluxStop units ahead of planned US launch
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amneal's risperidone extended-release injectable suspension approved by US FDA
Brain+ pilot shows Ayla therapy boosts cognitive outcomes in dementia care
Ascelia Pharma files NDA with FDA for liver imaging drug Orviglance
Biophytis secures EMA clearance to advance Phase 2 obesity trial
Valneva reports strong Phase 2 booster results for Lyme disease vaccine candidate VLA15